BIO 236Alternative Names: BIO236; LI-236
Latest Information Update: 08 Jun 2010
At a glance
- Originator Enhance Biotech
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Skin aging
Most Recent Events
- 18 May 2006 Development discontinued for Skin aging during 2006
- 22 Oct 2005 Phase-I clinical trials in Skin aging in USA (unspecified route)